澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MAYNE PHARMA GROUP LTD

3.000

-0.030-0.99%

成交量：8.38萬

成交額：25.27萬

市值：2.46億

市盈率：14.45

高：3.050

開：3.050

低：2.995

收：3.030

52周最高：6.500

52周最低：2.040

股本：8,189.09萬

流通股本：6,699.72萬

量比：0.25

換手率：0.13%

股息：- -

股息率：- -

每股收益(TTM):0.208

每股收益(LYR):0.208

淨資產收益率：8.20%

總資產收益率：-1.73%

市淨率：0.63

市盈率(LYR):14.45

資料載入中...

總覽公司新聞資訊公告

Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議

Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策

異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心

Mayne Pharma Group持續評估資本配置策略或考慮實施市場股票回購計劃

MAYNE PHARMA GROUP LTD：南澳大利亞索爾茲伯裏生產基地預計影響甚微，因出口美國產品多為仿製藥

Mayne Pharma旗下多款品牌皮膚科藥品或面臨新232條款關税

Mayne Pharma美國皮膚科仿製藥全線產品有望獲關税豁免

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/MYX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":3,"timestamp":1789539120000,"preClose":3.03,"halted":0,"volume":83795,"delay":0,"changeRate":-0.009900990099009837,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"已收盤","change":-0.03,"latestTime":"09-16 16:12:00 AEST","open":3.05,"high":3.05,"low":2.995,"amount":252732,"amplitude":0.018152,"askPrice":3.06,"askSize":766,"bidPrice":3,"bidSize":3298,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":3.03,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.249674,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3.03,"auctionPrice":3,"auctionVolume":1271,"auctionTime":1789539004933,"referencePrice":3,"referenceTime":1789540920650,"auction":3,"marketStatus":"盘后竞价","timestamp":1789539004933}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":0.249674,"shares":81890887,"dividePrice":0,"high":3.05,"amplitude":0.018152,"preClose":3.03,"low":2.995,"week52Low":2.04,"pbRate":"0.63","psRate":"0.64","week52High":6.5,"institutionHeld":0,"latestPrice":3,"committee":0.623031,"eps":0.207588,"divideRate":0,"volume":83795,"delay":0,"ttmEps":0.207588,"open":3.05,"prevYearClose":3.11,"prevWeekClose":2.96,"prevMonthClose":3.1,"prevQuarterClose":2.79,"fiveDayClose":3.18,"twentyDayClose":3.23,"sixtyDayClose":2.38,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132428558","title":"Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1132428558","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132428558?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:52","pubTimestamp":1789429933,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团宣布，已与Italfarmaco S.a签署了一项为期五年的独家许可协议。该协议针对Blissel在澳大利亚市场的推广与分销权。此举标志着Mayne Pharma在女性健康领域的战略布局进一步深化。Mayne Pharma方面表示，此次合作契合其专注于专科治疗领域的长期发展策略。通过引入Blissel这一产品，公司意在强化其在澳大利亚医疗市场中的竞争地位。而Italfarmaco则借助Mayne Pharma的本地网络，实现产品的快速渗透与市场拓展。投资者可密切关注该合作对Mayne Pharma营收结构的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174993621","title":"Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策","url":"https://stock-news.laohu8.com/highlight/detail?id=1174993621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174993621?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 06:25","pubTimestamp":1777501505,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团今日发布声明，明确表示公司首席执行官在涉及向其本人授予激励措施的薪酬决策过程中全程回避。该制药企业强调，相关薪酬决议完全由董事会下设的薪酬委员会独立制定，确保公司治理流程符合最高标准的透明性与规范性要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161898046","title":"異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1161898046","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161898046?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 08:17","pubTimestamp":1777421842,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd（ASX: MYX）今日盘中大涨5.58%，引起了市场的广泛关注。消息面上，该公司表示正在持续评估最优资本配置方案，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值，这提振了投资者信心。该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。此次股价上涨反映了市场对公司潜在积极举措的乐观预期。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136228232","title":"Mayne Pharma Group持續評估資本配置策略 或考慮實施市場股票回購計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1136228232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136228232?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 07:37","pubTimestamp":1777419437,"startTime":"0","endTime":"0","summary":"澳大利亚制药企业Mayne Pharma Group Ltd（ASX: MYX）近日表示，公司正在持续评估最优资本配置方案。据悉，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。\n该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139649848","title":"MAYNE PHARMA GROUP LTD：南澳大利亞索爾茲伯裏生產基地預計影響甚微，因出口美國產品多為仿製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1139649848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139649848?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 07:46","pubTimestamp":1775519173,"startTime":"0","endTime":"0","summary":"MAYNE PHARMA GROUP LTD 位于南澳大利亚州索尔兹伯里的生产基地预计将受到极小影响。这一判断主要基于其出口至美国市场的产品结构中，仿制药占据了主导地位。此类产品通常具有稳定的市场需求和成熟的供应链体系，能够有效缓冲外部环境变化带来的潜在冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114491474","title":"Mayne Pharma旗下多款品牌皮膚科藥品或面臨新232條款關税","url":"https://stock-news.laohu8.com/highlight/detail?id=1114491474","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114491474?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 07:44","pubTimestamp":1775519054,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd（ASX: MYX）近日披露，公司旗下多款品牌皮肤科药品可能被纳入美国新实施的232条款关税清单。这一潜在关税措施若生效，或将影响相关产品在美国市场的定价竞争力。公司表示正在评估具体影响范围，并将适时采取应对策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131205851","title":"Mayne Pharma美國皮膚科仿製藥全線產品有望獲關税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=1131205851","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131205851?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 07:43","pubTimestamp":1775519004,"startTime":"0","endTime":"0","summary":"根据最新公告，Mayne Pharma Group Ltd旗下在美国市场销售的全部皮肤科仿制药产品预计将获得关税豁免资格。这一政策若正式实施，将显著提升该公司产品在美国市场的价格竞争力。\n此次关税豁免涵盖Mayne Pharma在美国 dermatology generics（皮肤科仿制药）领域的完整产品组合。作为专业制药企业，该公司在皮肤科治疗领域拥有丰富的产品线和成熟的市场渠道。\n行业分析指出，关税豁免将直接降低产品进口成本，有利于企业优化利润空间并加强市场拓展。在当前全球贸易环境复杂多变的背景下，此项政策对专业制药企业的发展具有积极意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}